News about "Clinical Trials"

UK Life Sciences Attracts Investment to Create Jobs and Faster Patient Treatments

The UK life sciences sector has attracted over £3 billion in public-private investment in the past year, accelerating innovation, creating jobs, and improving patient access to new treatments.

Clinical Trials | 10/07/2026 | By News Bureau

Ionis Completes Enrollment in Phase 3 REVEAL Study for Angelman Syndrome

Ionis has completed enrollment in the pivotal Phase 3 REVEAL study of obudanersen for Angelman syndrome, with topline clinical trial results expected in the second half of 2027.

Clinical Trials | 06/07/2026 | By Akanki |  150

US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy

The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).

Clinical Trials | 26/06/2026 | By News Bureau |  178

Boehringer Ingelheim Launches 3 Phase 3 Trials to Advance Precision Oncology in Hard-to-Treat Cancers

Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.

Clinical Trials | 23/06/2026 | By News Bureau |  190

Suven Life Sciences to Showcase Differentiated CNS Clinical Candidates at BIO International Convention 2026

Suven Life Sciences will showcase its differentiated CNS clinical portfolio at BIO International Convention 2026, featuring late-stage drug candidates for Alzheimer’s agitation, Major Depressive Disorder (MDD), narcolepsy, Parkinson’s-related cognitive impairment, and other CNS disorders.

Clinical Trials | 22/06/2026 | By News Bureau |  124

Australia Approves MINJUVI (tafasitamab) for Relapsed or Refractory Follicular Lymphoma

Australia approves MINJUVI (tafasitamab) with rituximab and lenalidomide, the first chemo-free dual-targeted therapy for relapsed follicular lymphoma.

Clinical Trials | 24/04/2026 | By News Bureau

Mabwell Launches Phase 3 Trial of Nectin-4 ADC 9MW2821 for Triple-Negative Breast Cancer

Mabwell launches Phase 3 study of 9MW2821, the world’s first Nectin-4 ADC for TNBC, marking its fourth pivotal clinical trial.

Clinical Trials | 23/04/2026 | By News Bureau |  152

AstraZeneca's Tozorakimab Hits Key Phase 3 Goal in COPD Trial

AstraZeneca reports positive Phase III MIRANDA trial results for tozorakimab in COPD, marking its third successful pivotal study and reinforcing the potential of its IL-33-targeting biologic to transform respiratory care.

Clinical Trials | 21/04/2026 | By News Bureau |  121

OS Therapies files patent for immune-response biomarker linked to cancer immunotherapy

New data from the Phase IIb trial of OST-HER2 shows distinct immune signatures tied to improved survival outcomes, supporting accelerated approval discussions with global regulators.

Clinical Trials | 20/04/2026 | By News Bureau |  108

UK Accelerates Clinical Trials, Slashing Set-Up Time to Boost Patient Access

Government-backed reforms and Euro 137 million investment cut trial start times significantly, enabling faster access to innovative treatments through the National Health Service.

Clinical Trials | 17/04/2026 | By News Bureau |  107